JAK inhibition as a therapeutic strategy for immune and inflammatory diseases | Nature Reviews Drug Discovery
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases - ScienceDirect
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases | Journal of Medicinal Chemistry
Ruxolitinib | CAS 941678-49-5 | InvivoGen
Janus kinase 3 inhibitor - Wikipedia
Current and future status of JAK inhibitors - The Lancet
JAK inhibitors for the treatment of autoimmune and inflammatory diseases - ScienceDirect
JAK inhibitors prevent JAK activation. The signaling cascade that... | Download Scientific Diagram
JAK Inhibitors and FDA Warnings: What Arthritis Patients Need to Know
Selective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteine - preLights
Frontiers | Emerging Topical and Systemic JAK Inhibitors in Dermatology
Dermatologiske patienter kan vente sig meget af JAK-hæmmere
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19 | Science Immunology
The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions - Journal of Allergy and Clinical Immunology
A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor | Journal of Medicinal Chemistry
Phase 2 and 3 Trials of JAK Inhibitors For Atopic Dermatitis: A Review - Practical Dermatology
Pharmaceuticals | Free Full-Text | Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring | Dermatology and Therapy
